Pharmaceutical composition for the treatment or prevention of diseases involving obesity, diabetes, metabolic syndrome, neuro-degenerative diseases and mitochondria dysfunction diseases
Provided is a pharmaceutical composition for the treatment and prevention of obesity, diabetes, metabolic syndromes, degenerative diseases and mitochondrial dysfunction-related diseases, comprising: a therapeutically effective amount of a compound represented by Formula I below, or a pharmaceutically acceptable salt, prodrug, solvate or isomer thereof, and a pharmaceutically acceptable carrier, a diluent or an excipient, or any combination thereof. wherein R 1 through R 8 and n are as defined in this disclosure.
1. A method of treating a liver disease, comprising
administering to a subject in need thereof a pharmaceutical composition comprising:
(a) a therapeutically effective amount of a compound represented by Formula I:
wherein
R 1 and R 2 are each independently hydrogen, halogen, alkoxy, hydroxy or lower alkyl having 1 to 6 carbon atoms;
R 3 , R 4 , R 5 , R 6 , R 7 and R 8 are each independently hydrogen, hydroxy, C 1 -C 20 alkyl, alkene or alkoxy, cycloalkyl, heterocycloalkyl, aryl or heteroaryl, or two substituents of R 3 to R 8 may be taken together to form a cyclic structure; and
n is 0 or 1, with proviso that when n is 0, carbon atoms adjacent to n form a cyclic structure via a direct bond;
or a pharmaceutically acceptable salt thereof, and
(b) a pharmaceutically acceptable carrier, a diluent or an excipient, or any combination thereof,
wherein the liver disease is selected from the group consisting of a fatty liver, hepatic failure, liver function failure, and hepatomegaly.
2. The method according to claim 1 , wherein the compound of Formula I is selected from the group consisting of compounds of Formula II and Formula III:
wherein, R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 and R 8 are as defined in Formula I,
or a pharmaceutically acceptable salt thereof.
3. The method according to claim 1 , wherein each R 1 and R 2 is hydrogen.
4. The method according to claim 2 , wherein the compound of Formula II is a compound of Formula IIa wherein R 1 , R 2 and R 4 are independently hydrogen, or a compound of Formula IIb wherein R 1 , R 2 and R 6 are independently hydrogen:
or a pharmaceutically acceptable salt thereof.
5. The method according to claim 2 , wherein the compound of Formula III is a compound of Formula IIIa wherein R 1 , R 2 , R 5 , R 6 , R 7 and R 8 are independently hydrogen:
or a pharmaceutically acceptable salt thereof.
6. The method according to claim 1 , wherein the compound of Formula I is β-lapachone having the following formula:
or a pharmaceutically acceptable salt thereof.